

Supplementary Table S2. Hsp90 inhibitors already tested against the yeast *Candida* and their activity alone *in vitro* and in combination *in vitro* or in *Galleria mellonella* model according to literature data.

Compounds	Candida species	Activity alone	Activity in combination	References
NTD-Hsp90 inhibitors				
RA	<i>C. albicans</i> <i>C. glabrata</i>	MIC 8 - >20 μ M	-Synergistic activity with fluconazole -Diminution of tolerance to voriconazole -Diminution of the micafungin paradoxical effect -Diminution of caspofungin resistance	[25-27]
STA9090	<i>C. albicans</i>	IC ₅₀ > 40 μ M	-Weak synergistic activity with fluconazole	[27,28]
NVP-AUY922	<i>C. albicans</i>	IC ₅₀ > 40 μ M	-Weak synergistic activity with fluconazole	[27,28]
GA	The five most common species*	IC ₅₀ 5.7-22.8 μ M	-Synergistic activity with triazoles and echinocandins	[29-31]
17-AAG	<i>C. albicans</i>	No indicated	-Synergistic effect with fluconazole in <i>G. mellonella</i>	[32]
17-DMAG	<i>C. albicans</i>	No indicated	-Synergistic effect with fluconazole in <i>G. mellonella</i>	[32]
SNX-2112	<i>C. albicans</i>	IC ₅₀ > 40 μ M	No indicated	[27]
HSP990	The five most common species*	IC ₈₀ > 168 μ M	-Synergistic activity with fluconazole	[28]
CTD-Hsp90 inhibitors				
SIL	<i>C. albicans</i> <i>C. krusei</i> <i>C. tropicalis</i>	MIC 2 mM	-Antagonistic effect with nystatin	[33]
EGCG	The five most common species*	MIC 8.5-34.1 μ M	-Synergistic effect with azoles	[34,35]

*The five most common species are *C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. tropicalis* and *C. krusei*